Par and Perrigo Pharmaceuticals Urged to Address and Remedy the National Shortage of Injectable Oestrogen

Published on September 30, 2016 by CreagerCole Communications


Callen-Lorde

Callen-Lorde Community Health Center is leading a national coalition – with partners from Fenway Health in Boston and Treatment Action Group in New York City - that has collected 570 signatures for a petition calling on pharmaceutical companies Par and Perrigo to address and remedy the national shortage of injectable oestrogen.

In July, Callen-Lorde warned of potential public health risk for transgender women and transfeminine people due to a nationwide shortage of some generic and brand name injectable oestrogen. At that time, the makers of the drugs reported manufacturing delays in getting the medications to the market.
A sign on letter was circulated nationally. In New York City, First Lady Chirlane McCray – in her capacity as Co-Chair for the Commission on Gender Equity – signed the letter.

“The downstream medical and mental health implications from interruptions of life-sustaining therapies that keep transgender women engaged in healthcare are dire,” said Dr. Demetre Daskalakis, Assistant Commissioner for the NYC Health Department’s Bureau of HIV. “It is critical that this shortage of injectable oestrogen be addressed as the emergency that it is.”

After the letter was delivered in September, Callen-Lorde heard from Par Pharmaceutical President Paul Campanelli, who said that a new raw material in the Delestrogen requires FDA approval. He stated that the product was manufactured, and they estimated FDA approval would be received by early 2017. He also expressed that the company understood the importance of the product to the American consumer.

Callen-Lorde has heard that Perrigo, which manufacturers the generic counterpart, estradiol valerate, is expected to restock the drug in October.

“The lack of injectable oestrogen for our transgender women patients is a public health crisis,” said Wendy Stark, Executive Director of Callen-Lorde. “We’re pleased that this issue is getting the attention it deserves and remain cautiously optimistic that the pharmaceutical companies and FDA can restock these life-saving drugs.”

Hormone therapy to affirm gender identity is a medically necessary intervention for many transgender individuals. Support from public health providers and community alike has elevated the issue in the press.

Contact:

Cindi Creager, CreagerCole Communications

(646) 279-4559, cindi@creagercole.com

Related Posts Plugin for WordPress, Blogger...
CreagerCole Communications

CreagerCole Communications

" I teach you how to break down all the jargon and get to the point. My disarming, yet laser-focused style, puts you at ease while building up your confidence to handle all media and public speaking appearances."

More Posts - Website

Follow Me:
TwitterFacebook

Tags: , , , , , , , , , , , , , , , ,

Category: USA Transgender

  • Welcome to us

    Welcome To LGBTnewswire.eu !

    This site are made for journalist, bloggers, magazines, radio and television that covers LGBT news.

    The service is free to use as long you follow some easy source credit rules.

  • Information

  • Remember to read FAQ Publisher before using the content filed under LGBTnewswire.eu .

  • Subscribe to Blog via Email

    Enter your email address to subscribe to this website and receive notifications of new press releases by email.

  • Search

  • Donate Today